This systematic review aims to assess the long-term cardiovascular outcomes associated with GLP-1 RA use in adults with T2DM, compare their cardiovascular effects with other glucose-lowering medications, and evaluate their safety profile in long-term use. This evidence concerns the gene GLP1R and type 2 diabetes mellitus.